1. Home
  2. LARK vs SABS Comparison

LARK vs SABS Comparison

Compare LARK & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Landmark Bancorp Inc.

LARK

Landmark Bancorp Inc.

N/A

Current Price

$28.24

Market Cap

167.8M

Sector

Finance

ML Signal

N/A

Logo SAB Biotherapeutics Inc.

SABS

SAB Biotherapeutics Inc.

N/A

Current Price

$3.95

Market Cap

181.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
LARK
SABS
Founded
1885
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
167.8M
181.4M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
LARK
SABS
Price
$28.24
$3.95
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$9.00
AVG Volume (30 Days)
9.0K
303.1K
Earning Date
02-03-2026
11-13-2025
Dividend Yield
2.78%
N/A
EPS Growth
38.73
N/A
EPS
2.84
N/A
Revenue
$64,367,999.00
$114,698.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$10.12
N/A
Revenue Growth
12.95
N/A
52 Week Low
$20.99
$1.00
52 Week High
$29.56
$6.60

Technical Indicators

Market Signals
Indicator
LARK
SABS
Relative Strength Index (RSI) 59.69 58.03
Support Level $28.00 $3.54
Resistance Level $28.98 $4.04
Average True Range (ATR) 0.83 0.29
MACD 0.01 -0.02
Stochastic Oscillator 44.29 71.91

Price Performance

Historical Comparison
LARK
SABS

About LARK Landmark Bancorp Inc.

Landmark Bancorp Inc is the bank holding company for Landmark National Bank, which is dedicated to providing quality financial and banking services. The Bank has continued to focus on increasing its originations of commercial, commercial real estate (CRE), and agricultural loans, which management believes will be more profitable and provide more growth for the Bank than traditional one-to-four-family residential real estate lending. In addition, it also invests in certain investment and mortgage-related securities using deposits and other borrowings as funding sources. Its primary deposit gathering and lending markets are geographically diversified with locations in central, eastern, southeast, and southwest Kansas.

About SABS SAB Biotherapeutics Inc.

SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.

Share on Social Networks: